Atea Pharmaceuticals Inc (AVIR) Stock Price, Quote & News

Company Profile

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 284 8891

Website: ateapharma.com

Address:

225 Franklin Street, Suite 2100, Boston, United States

Chrissytina Feb. 2 at 7:24 PM

$AVIR I really wanted to be happy it was up…but I knew better 🤦🏼‍♀️

0 · Reply

Cocky_day_trader Feb. 2 at 12:09 AM

$AVIR following and processing

0 · Reply

OnlyFibs Jan. 31 at 9:26 PM

$AVIR is a textbook breakout! 🧬📈 Reclaiming $4.14 as support is the massive pivot bulls have been waiting for. With a fresh Golden Cross and Phase 3 HCV data looming in mid-2026, the $301M cash cushion makes this a high-conviction "safety" play in biotech. 🛡️🚀 🐂 Bulls: Must hold $4.14 and clear $4.34 (52-week high) to target $6.12. 🐻 Bears: Looking for a break below $3.80 to invalidate the breakout. Confirming level: $4.34 #AVIR #Biotech #AteaPharma #GoldenCross #hovdid

0 · Reply

StockScanners Jan. 31 at 9:19 AM

$AVIR keep watch if this holds above 4.10

0 · Reply

StockScanners Jan. 27 at 3:36 AM

$AVIR reached 4.01

0 · Reply

OfficialStocktwitsUser Jan. 26 at 10:48 PM

$AVIR RSI: 68.10, MACD: 0.1360 Vol: 0.19, MA20: 3.57, MA50: 3.31 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

WINGI_Investments Jan. 26 at 3:12 PM

$AVIR

0 · Reply

SammoStocko Jan. 26 at 11:20 AM

$AVIR looking at getting into this? Am I late? What’s on the horizon that could make this go parabolic?

0 · Reply

StockScanners Jan. 24 at 5:20 AM

$AVIR keep watch if this holds above 3.90

0 · Reply

peepthestamp Jan. 24 at 12:08 AM

$AVIR

0 · Reply

Atea Pharmaceuticals, Inc. (AVIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 8, 2026, 7:00 AM EST - 27 days ago

Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 7:00 AM EST - 4 weeks ago

Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 23, 2025, 5:51 AM EST - 6 weeks ago

Atea Pharmaceuticals: Potential Best-In-Class HCV Cure With Pivotal Readouts In 2026

Dec 22, 2025, 7:00 AM EST - 6 weeks ago

Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Nov 19, 2025, 7:00 AM EST - 2 months ago

Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference

Nov 13, 2025, 2:31 PM EST - 2 months ago

Atea Pharmaceuticals, Inc. (AVIR) Discusses Next-Generation Hepatitis C Treatment Developments and Clinical Advancements Transcript

Nov 12, 2025, 7:01 PM EST - 2 months ago

Atea Pharmaceuticals, Inc. (AVIR) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 4:05 PM EST - 2 months ago

Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 7, 2025, 8:00 AM EST - 3 months ago

Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

Nov 5, 2025, 7:00 AM EST - 3 months ago

Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025

Oct 22, 2025, 7:00 AM EDT - 3 months ago

Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025

Oct 7, 2025, 8:00 AM EDT - 4 months ago

Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

Sep 9, 2025, 5:51 PM EDT - 5 months ago

Atea Pharmaceuticals, Inc. (AVIR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 2, 2025, 7:00 AM EDT - 5 months ago

Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 8, 2025, 3:29 PM EDT - 6 months ago

Atea Pharmaceuticals, Inc. (AVIR) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 6 months ago

Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 7:00 AM EDT - 6 months ago

Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025

Jun 24, 2025, 7:00 AM EDT - 8 months ago

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

May 12, 2025, 4:11 PM EDT - 9 months ago

Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025, 7:00 AM EDT - 9 months ago

Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025

May 1, 2025, 7:00 AM EDT - 9 months ago

Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025

Apr 23, 2025, 7:00 AM EDT - 10 months ago

Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025

Apr 17, 2025, 7:00 AM EDT - 10 months ago

Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

Apr 9, 2025, 7:00 AM EDT - 10 months ago

Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Mar 31, 2025, 7:04 PM EDT - 11 months ago

Driver Notifies Atea Pharmaceuticals of Withdrawal of Notice of Nomination

Mar 26, 2025, 1:58 PM EDT - 11 months ago

Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value

Mar 26, 2025, 8:00 AM EDT - 11 months ago

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Mar 21, 2025, 5:54 PM EDT - 11 months ago

Atea Pharmaceuticals Issues Statement Regarding Director Nominations

Mar 19, 2025, 7:00 AM EDT - 11 months ago

Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025

Mar 6, 2025, 6:14 PM EST - 11 months ago

Atea Pharmaceuticals, Inc. (AVIR) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 4:05 PM EST - 11 months ago

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 27, 2025, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025

Feb 24, 2025, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

Jan 8, 2025, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 5:05 PM EST - 1 year ago

Concerned Shareholder Group Calls for Atea Pharmaceuticals to Appoint a New, Shareholder-Oriented Lead Independent Director to Oversee Strategic Review Process

Dec 16, 2024, 5:00 AM EST - 1 year ago

Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships

Dec 4, 2024, 3:14 PM EST - 1 year ago

After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study

Dec 4, 2024, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)

Nov 26, 2024, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference

Nov 15, 2024, 11:00 AM EST - 1 year ago

Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024

Nov 9, 2024, 1:14 PM EST - 1 year ago

Atea Pharmaceuticals, Inc. (AVIR) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:05 PM EST - 1 year ago

Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 30, 2024, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024

Sep 13, 2024, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19

Aug 28, 2024, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir's Metabolic Activation Pathway

Aug 11, 2024, 12:13 PM EDT - 1 year ago

Atea Pharmaceuticals, Inc. (AVIR) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024

May 29, 2024, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference

May 22, 2024, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024

Chrissytina Feb. 2 at 7:24 PM

$AVIR I really wanted to be happy it was up…but I knew better 🤦🏼‍♀️

0 · Reply

Cocky_day_trader Feb. 2 at 12:09 AM

$AVIR following and processing

0 · Reply

OnlyFibs Jan. 31 at 9:26 PM

0 · Reply

StockScanners Jan. 31 at 9:19 AM

$AVIR keep watch if this holds above 4.10

0 · Reply

StockScanners Jan. 27 at 3:36 AM

$AVIR reached 4.01

0 · Reply

OfficialStocktwitsUser Jan. 26 at 10:48 PM

0 · Reply

WINGI_Investments Jan. 26 at 3:12 PM

$AVIR

0 · Reply

SammoStocko Jan. 26 at 11:20 AM

$AVIR looking at getting into this? Am I late? What’s on the horizon that could make this go parabolic?

0 · Reply

StockScanners Jan. 24 at 5:20 AM

$AVIR keep watch if this holds above 3.90

0 · Reply

peepthestamp Jan. 24 at 12:08 AM

$AVIR

0 · Reply

Tfizzle Jan. 23 at 6:18 PM

$AVIR

0 · Reply

intrader Jan. 23 at 3:59 PM

$AVIR I'm in. Target $6.50+

0 · Reply

Following_the_trend Jan. 23 at 3:51 PM

$AVIR Moving well today. Strange w/3K following, not many posts. I have a small position for a few months now.

0 · Reply

Cutlass Jan. 23 at 3:43 PM

$AVIR 330M in cash, gap at 38 ⏰

0 · Reply

Cutlass Jan. 23 at 3:38 PM

$AVIR Very June 2024

0 · Reply

Cutlass Jan. 23 at 3:29 PM

$AVIR Some R in 4.60 neighborhood - ✍️

0 · Reply

Cutlass Jan. 23 at 3:22 PM

$AVIR Just buy them out already Lol 🤠

0 · Reply

OfficialStocktwitsUser Dec. 29 at 3:50 PM

$AVIR RSI: 70.72, MACD: 0.1026 Vol: 0.19, MA20: 3.23, MA50: 3.20 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

DiaphragmD Dec. 27 at 5:14 AM

$AVIR Trading dynamics suggest reliability now matters more than momentum bursts. Resource allocation choices will signal strategic maturity. Execution consistency is the fastest path to confidence rebuilding. Compounding requires operational consistency.

0 · Reply

FATSTAX Dec. 24 at 7:09 PM

$SPY $AVIR

0 · Reply

kubota2323 Dec. 24 at 3:31 PM

$KYTX adding $AVIR now . Very Bullish on both

0 · Reply

BioTechHealthX Dec. 24 at 5:07 AM

$AVIR Atea Pharmaceuticals Inc (NASDAQ:AVIR) has completed enrollment in a major Phase 3 hepatitis C trial, setting the stage for pivotal mid-2026 data that could reshape the antiviral treatment landscape. https://biotechhealthx.com/biotech-news/why-atea-pharmaceuticals-inc-avir-could-be-entering-its-most-important-phase-yet/

0 · Reply

Market Cap	331.26M
Revenue (ttm)	0.00
Net Income (ttm)	-168.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	339,252
Avg Vol	437,866
Day's Range	N/A - N/A
Shares Out	78.13M
Stochastic %K	68%
Beta	0.08
Analysts	Sell
Price Target	$6.00